|How to cite this article:
Wiwanitkit V. Immunomodulatory adjunctive treatment options for Ebola virus disease: Possibility and how?. Ann Trop Med Public Health 2016;9:197
|How to cite this URL:
Wiwanitkit V. Immunomodulatory adjunctive treatment options for Ebola virus disease: Possibility and how?. Ann Trop Med Public Health [serial online] 2016 [cited 2020 Sep 21];9:197. Available from: https://www.atmph.org/text.asp?2016/9/3/197/181662
Ebola virus disease is the present concern in public health. Finding effective new therapeutic technique is the urgent requirement. The recent report on “immunomodulatory adjunctive treatment options for Ebola virus disease” is very interesting. In fact, in the present day, the immunomodulation technique becomes a new alternative way for management of several infectious diseases. For the Ebola virus disease, there is still no conclusion on the effective management. The management is generally supportive, similar to any other hemorrhagic viral diseases. To use immunomodulatory adjunctive treatment, there are two big questions. First, the possibility of the technique should be discussed. Although there are many drugs (such as statins) that are mentioned for the ability to modify the host report that might be useful for management of the infection. The question that remains is the unclear immunopathogenesis of the Ebola virus disease and the unclear pharmacological reaction of those drugs. The big consideration, based on the mentioned unclear issues, is the lack for knowledge on how to dose the immunomodulative drugs. Too much or too little immune-modification might be problematic and this might result in unwanted reaction. Second, how to perform this kind of therapy should also be discussed. With the lack of data, it is very hard to decide when to start the treatment, and what is the best period for applying such treatment. These issues remain as interesting aspect for further researches on Ebola virus disease.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
Fedson DS. Immunomodulatory adjunctive treatment options for Ebola virus disease patients: Another view. Intensive Care Med 2015;41:1383.
Wiwanitkit V. Ebola virus infection: What should be known? N Am J Med Sci 2014;6:549-52.
Kilgore PE, Grabenstein JD, Salim AM, Rybak M. Treatment of ebola virus disease. Pharmacotherapy 2015;35:43-53.
Source of Support: None, Conflict of Interest: None